Date:1/27/2010

d these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

    For more information, please contact:

    Company Contact:
     Mr. Y. Tristan Kuo
     Chief Financial Officer
     China Biologic Products, Inc.
     Phone: +86-538-6202206
     Email: IR@chinabiologic.com
     Web:   http://www.chinabiologic.com

    Investor Relations Contact:
     CCG Investor Relations
     Ms. Elaine Ketchmere, Partner
     Phone: +1-310-954-1345
     Email: elaine.ketchmere@ccgir.com

     Mr. Crocker Coulson, President
     Phone: +1-646-213-1915
     Email: crocker.coulson@ccgir.com
     Web:   http://www.ccgirasia.com
'/>"/>
SOURCE  China Biologic Products, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 
Related biology technology :

1. China Yongxin Pharmaceuticals Plans to Open Eighteen New Stores in 2010 to Further Expand Customer Base and Increase Market Share
2. China YCT International Group, Inc. Announces That the State Intellectual Property Office of the Peoples Republic of China has Approved a Patent to its Operating Subsidiary, Shandong Spring Pharmaceutical Co. Ltd.
3. China Yongxin Pharmaceuticals Opened Three New Stores in 2009 and Expanded Customer Base
4. China Yongxin Pharmaceuticals Projects Higher Net Income and EPS on Reduced Revenue for Full-Year 2009
5. China Cord Blood Corporation Announces Partial Exercise of Over-Allotment Option
6. Sinovacs CEO Weidong Yin Presented with Annual Innovation Award by China Central Television
7. American Oriental Bioengineering Announces the Inclusion of 158 Drugs in Chinas National Insurance Catalog
8. China Sky Medical, Inc. Has 30 Medicines that will Be Included in Chinas National Insurance Directory
9. China Biologic Products to Ring NASDAQ Opening Bell
10. Simcere Announces 105 Drugs Included in Chinas National Drug Reimbursement List
11. Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit